Treatment of chronic lymphocytic leukaemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone.

[1]  N. Nissen,et al.  Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. , 2009, Acta medica Scandinavica.

[2]  L. Brandt,et al.  Therapeutic effect of Leo 1031, an alkylating corticosteroid ester, in lymphoproliferative disorders. I. chronic lymphocytic leukaemia. , 2009, Acta medica Scandinavica.

[3]  B. Johansson,et al.  Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma. , 1983, European journal of cancer & clinical oncology.

[4]  R. Hartsock,et al.  Moderate versus intensive chemotherapy of prognostically favorable non‐Hodgkin's lymphoma a progress report , 1980, Cancer.

[5]  C. Bloomfield,et al.  IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA , 1980, The Lancet.

[6]  W. Knospe.  Does therapy alter the natural history and prognosis of chronic lymphocytic leukemia? , 1979, International journal of radiation oncology, biology, physics.

[7]  R. Johnson.  Treatment of chronic lymphocytic leukemia by total body irradiation alone and combined with chemotherapy. , 1979, International journal of radiation oncology, biology, physics.

[8]  T. Möller,et al.  Continuous treatment of non-Hodgkin's malignant lymphoma with prednimustine (Leo 1031). , 1978, Oncology.

[9]  M. Liepman,et al.  The treatment of chronic lymphocytic leukemia with COP chemotherapy , 1978, Cancer.

[10]  K. Rai,et al.  Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. , 1977, Blood.

[11]  L. Brandt,et al.  Therapeutic effect of prednimustine (LEO 1031) in various types of leukaemia. , 1977, European journal of cancer.

[12]  B. Simonesson.  Evidence for a Glucocorticoid Receptor in Human Leukocytes , 1976 .

[13]  G. Murphy,et al.  Study of Leo-1031 (NSC-134087) in lymphocytic lymphoma and chronic lymphocytic leukemia. , 1976, Cancer treatment reports.

[14]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[15]  S. Perry,et al.  Cytoplasmic glucocorticoid-binding proteins in glucocorticoid-unresponsive human and mouse leukemic cell lines. , 1974, Cancer research.

[16]  W. Knospe,et al.  Bi‐weekly chlorambucil treatment of chronic lymphocytic leukemia , 1974 .

[17]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[18]  S. Perry,et al.  Studies of leukocyte kinetics in chronic lymphocytic leukemia. , 1968, Blood.

[19]  E. Gehan.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.

[20]  H. V. van Lier,et al.  Response to therapy as prognostic factor in chronic lymphocytic leukemia. , 1980, Acta haematologica.

[21]  R. Livingston,et al.  Single Agents in Cancer Chemotherapy , 1970, Springer US.